The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparative Evaluation of FDG-PET and GA-67 SPECT in Staging of Patients with Lymphoma.
 
Yoshiaki Nakamura
No Relationships to Disclose
 
Takeharu Yamanaka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Keisho Chin
No Relationships to Disclose
 
Haruhiko Cho
Honoraria - Bayer; Pfizer
 
Hitoshi Katai
No Relationships to Disclose
 
Masanori Terashima
Honoraria - Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst)
 
Seiji Ito
Honoraria - Chugai Pharma; Lilly; Olympus Medical Systems; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst)
 
Motohiro Hirao
No Relationships to Disclose
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Mitsuru Sasako
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Yasunori Emi
Honoraria - Chugai Pharma
 
Hideaki Bando
Research Funding - AstraZeneca; Sysmex
 
Yoshiyuki Kawashima
No Relationships to Disclose
 
Tetsu Fukunaga
No Relationships to Disclose
 
Masahiro Gotoh
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma; Kyowa Hakko Kirin; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Taiho Pharmaceutical
 
Takako Ishibashi
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Three-year outcomes of two phase II studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin in patients with stage III gastric cancer after D2 gastrectomy.
 
Kazuhiro Yoshida
Honoraria - Chugai Pharma; Daiichi Sankyo; EA Pharma; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Chugai Pharma; Daiichi Sankyo; EA Pharma; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha